Clinical Trials Directory

Trials / Unknown

UnknownNCT02243904

Study for Promotion of Health in Recycling Lead

Status
Unknown
Phase
Study type
Observational
Enrollment
270 (actual)
Sponsor
KU Leuven · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Study for Promotion of Health in Recycling Lead (SPHERL) is a prospective 2-year follow-up study of lead workers with exposure levels varying between and within individuals. SPHERL addresses to what extent between-subject differences or within-subject changes in lead exposure may have a measurable impact on blood pressure, the cardiovascular system, renal function, the autonomic nervous system, peripheral nervous conduction velocity, and neurocognitive function. At the beginning of December 2015, 70 participants were included in the study.

Detailed description

Background * Whether low-level lead exposure impacts on blood pressure, regulation of the cardiovascular system, glomerular or tubular renal function, sympathetic nervous modulation, peripheral nervous conduction velocity, and neurocognitive function remains uncertain. Study Population * SPHERL will enroll 500 lead recycling workers with changing lead exposure, who will be examined at baseline (2014-2015) and followed up at annual intervals for 2 years (2016-2017). Methods * Volunteers eligible for the study are (i) new and existing hires without previous occupational lead exposure who will be performing tasks with or without occupational lead exposure and (ii) existing hires with occupational lead exposure who will be transitioning to job tasks without occupational lead exposure within the next 2 years. * Blood lead concentration will be the main biomarker of exposure. * The main outcome variables are (i) blood pressure measured conventionally and by ambulatory monitoring, and analyzed as continuous or categorical variable, both cross-sectionally and longitudinally; (ii) indexes of glomerular and tubular renal function, (iii) heart rate variability analyzed in the frequency domain as measure of autonomous sympathetic modulation, (iv) peripheral nerve conductivity, (v) neurocognitive performance, (vi) and quality of life \[the EuroQOL five dimensions (EQ-5D) questionnaire\]. Expected Outcomes * Assuming a 4-fold or higher surge in the blood lead concentration, the study is powered to demonstrate over 2 years an acceleration in the age-related rise of systolic blood pressure by 1 to 4 mm Hg or an increase of the coefficient of multiple determination (R2) from 0.22 to 0.24 by adding the change in the blood lead concentration to models relating changes in blood pressure to three other covariables. The longitudinal design of our study complies with the temporality principle of the Bradford-Hill criteria for assessing possible causality between outcomes and exposure.

Conditions

Timeline

Start date
2015-08-01
Primary completion
2024-07-01
Completion
2024-12-31
First posted
2014-09-18
Last updated
2020-03-03

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT02243904. Inclusion in this directory is not an endorsement.